{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:22:03Z","timestamp":1787829723731,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,29]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Apixaban plays a crucial role in preventing cardioembolic events in patients with nonvalvular atrial fibrillation (NVAF). However, in clinical practice, physicians often adjust apixaban dosing based on kidney function, deviating from guideline-recommended dosing. This study investigated the effects of real-world, off-label apixaban dosing on long-term outcomes in patients with heart failure (HF), NVAF, and end-stage kidney disease (ESKD). We analyzed data from a HF registry of patients with NVAF and ESKD between 2018 and 2024. The inclusion criteria comprised all patients treated with apixaban. Patients were categorized according to the strength of the apixaban dose administered. Outcomes, including bleeding events, systemic thromboembolic events, and all-cause mortality, were compared. Among 480 patients, 265 (55.2%), with a mean age of 77.3\u2005\u00b1\u200510.1 years, received an off-label underdose of apixaban. Baseline characteristics, including CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      -VASc and HAS-BLED scores, were similar across groups. Over a median follow-up of 48 months, no significant differences in systemic thromboembolic events or mortality were observed between the off-label underdose group and those receiving standard doses or off-label overdoses (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.705). Similarly, no significant differences were observed in bleeding risk (underdose vs standard,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.600; overdose vs standard,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.395; underdose vs overdose,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.469). In multivariate analysis, the CHA\n                      <jats:sub>2<\/jats:sub>\n                      DS\n                      <jats:sub>2<\/jats:sub>\n                      -VASc score was an independent predictor of thromboembolic events (odds ratio 1.818, 95% confidence interval 1.081\u20133.058;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.024). In patients with HF, NVAF, and ESKD, off-label apixaban dosing was not associated with an increased risk of systemic thromboembolic events, mortality, or bleeding, highlighting the potential for personalized apixaban dosing based on patient-specific factors and pharmacokinetics, particularly in Asian populations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049075","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:06:22Z","timestamp":1780074382000},"page":"e49075","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Real-world off-label apixaban dosing and clinical outcomes in patients with heart failure and end-stage kidney disease"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-2422","authenticated-orcid":false,"given":"Sung Il","family":"Im","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Hyun","family":"Bae","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong Joon","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Ho","family":"Heo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Na","family":"Kim","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Internal Medicine, Gospel Hospital, Kosin University College of Medicine, Busan, South Korea"},{"name":"Transplantation Research Institute, Kosin University College of Medicine, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonsoon","family":"Jung","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Internal Medicine, Gospel Hospital, Kosin University College of Medicine, Busan, South Korea"},{"name":"Transplantation Research Institute, Kosin University College of Medicine, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hark","family":"Rim","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Internal Medicine, Gospel Hospital, Kosin University College of Medicine, Busan, South Korea"},{"name":"Transplantation Research Institute, Kosin University College of Medicine, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Pil","family":"Cho","sequence":"additional","affiliation":[{"name":"MEZOO Co., Ltd., Wonju-si, Gangwon-do, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hwan","family":"Park","sequence":"additional","affiliation":[{"name":"MEZOO Co., Ltd., Wonju-si, Gangwon-do, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Sik","family":"Shin","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Internal Medicine, Gospel Hospital, Kosin University College of Medicine, Busan, South Korea"},{"name":"Transplantation Research Institute, Kosin University College of Medicine, Busan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260827","first-page":"e20250036","article-title":"Brazilian dialysis survey from 1999 to 2023: trends in demographics, nutritional status, primary disease, and viral serology.","volume":"47","author":"Nerbass","year":"2025","journal-title":"J Bras Nefrol"},{"key":"R2-20260827","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s12911-025-03278-z","article-title":"ECG-based deep learning for chronic kidney disease detection and cardiovascular risk prediction.","volume":"25","author":"Tsai","year":"2025","journal-title":"BMC Med Inform Decis Mak"},{"key":"R3-20260827","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12882-016-0368-6","article-title":"Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis.","volume":"17","author":"Tan","year":"2016","journal-title":"BMC Nephrol"},{"key":"R4-20260827","doi-asserted-by":"crossref","first-page":"e0230189","DOI":"10.1371\/journal.pone.0230189","article-title":"Association of atrial fibrillation and clinical outcomes in adults with chronic kidney disease: a propensity score-matched analysis.","volume":"15","author":"Zhang","year":"2020","journal-title":"PLoS One"},{"key":"R5-20260827","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/europace\/euz340","article-title":"Secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease: a nationwide cohort study.","volume":"22","author":"Christensen","year":"2020","journal-title":"Europace"},{"key":"R6-20260827","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/jcm9010123","article-title":"Stroke prophylaxis in patients with atrial fibrillation and end-stage renal disease.","volume":"9","author":"van Zyl","year":"2020","journal-title":"J Clin Med"},{"key":"R7-20260827","first-page":"e010595","article-title":"Adequacy of dialysis and incidence of atrial fibrillation in patients undergoing hemodialysis.","volume":"17","author":"Heo","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R8-20260827","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2215\/CJN.10921015","article-title":"Atrial fibrillation and risk of ESRD in adults with CKD.","volume":"11","author":"Bansal","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"R9-20260827","doi-asserted-by":"crossref","first-page":"e0212237","DOI":"10.1371\/journal.pone.0212237","article-title":"Evaluation of hemostasis in patients with end-stage renal disease.","volume":"14","author":"Gackler","year":"2019","journal-title":"PLoS One"},{"key":"R10-20260827","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/ejhf.3631","article-title":"Kidney status and events preceding death in heart failure: a real-world nationwide study.","volume":"27","author":"Zahir Anjum","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"R11-20260827","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jchf.2024.01.004","article-title":"Trajectories of kidney function in heart failure over a 15-year follow-up: clinical profiling and mortality.","volume":"12","author":"Zamora","year":"2024","journal-title":"JACC Heart failure"},{"key":"R12-20260827","first-page":"173","article-title":"Acute heart failure in the 2021 ESC heart failure guidelines: a scientific statement from the association for acute cardiovascular care (ACVC) of the European society of cardiology.","volume":"11","author":"Masip","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R13-20260827","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.3390\/jcm11237041","article-title":"Heart failure and cardiorenal syndrome: a narrative review on pathophysiology, diagnostic and therapeutic regimens-from a cardiologist\u2019s view.","volume":"11","author":"Mitsas","year":"2022","journal-title":"J Clin Med"},{"key":"R14-20260827","first-page":"860","article-title":"Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.","volume":"38","author":"Diener","year":"2017","journal-title":"Eur Heart J"},{"key":"R15-20260827","doi-asserted-by":"crossref","first-page":"1645823","DOI":"10.3389\/fcvm.2025.1645823","article-title":"Research progress on bleeding risk assessment models in anticoagulant therapy.","volume":"12","author":"Sen","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"R16-20260827","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism.","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"R17-20260827","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.jtha.2024.05.027","article-title":"Examining variability in the diagnosis and management of people with bleeding disorders of unknown cause: communication from the ISTH SSC Subcommittee on von Willebrand Factor.","volume":"22","author":"Kelly","year":"2024","journal-title":"J Thromb Haemost"},{"key":"R18-20260827","doi-asserted-by":"crossref","first-page":"e2017150","DOI":"10.1001\/jamanetworkopen.2020.17150","article-title":"Association of age with risk of kidney failure in adults with stage IV chronic kidney disease in Canada.","volume":"3","author":"Ravani","year":"2020","journal-title":"JAMA Network Open"},{"key":"R19-20260827","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s12933-025-02998-w","article-title":"Impact of type 2 diabetes on the relationship between chronic kidney disease and cardiovascular outcomes in heart failure across ejection fraction: observational study from the Swedish heart failure and the Swedish National diabetes registries.","volume":"24","author":"Merolla","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"R20-20260827","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jelectrocard.2016.07.019","article-title":"Challenges of ECG monitoring and ECG interpretation in dialysis units.","volume":"49","author":"Poulikakos","year":"2016","journal-title":"J Electrocardiol"},{"key":"R21-20260827","doi-asserted-by":"crossref","first-page":"e026605","DOI":"10.1161\/JAHA.122.026605","article-title":"Variability in nonvitamin K oral anticoagulant dose eligibility and adjustment according to renal formulae and clinical outcomes in patients with atrial fibrillation with and without chronic kidney disease: insights from ORBIT-AF II.","volume":"12","author":"Yao","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R22-20260827","doi-asserted-by":"crossref","first-page":"102584","DOI":"10.1016\/j.rpth.2024.102584","article-title":"Safety and efficacy of direct oral anticoagulants in chronic kidney disease: a meta-analysis.","volume":"8","author":"Tham","year":"2024","journal-title":"Res Pract Thrombosis Haemostasis"},{"key":"R23-20260827","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"R24-20260827","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"R25-20260827","doi-asserted-by":"crossref","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges.","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R26-20260827","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"R27-20260827","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation"},{"key":"R28-20260827","doi-asserted-by":"crossref","first-page":"321","DOI":"10.31083\/j.rcm2509321","article-title":"Safety and effectiveness outcomes between apixaban versus vitamin K antagonists in atrial fibrillation patients on dialysis.","volume":"25","author":"Guo","year":"2024","journal-title":"Rev Cardiovasc Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:01:00Z","timestamp":1787828460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":28,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049075","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"2025-09-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}